Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ProPhase Labs (PRPH) EBT Margin (2016 - 2025)

Historic EBT Margin for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to 792.3%.

  • ProPhase Labs' EBT Margin fell 2645400.0% to 792.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 676.18%, marking a year-over-year decrease of 63536900.0%. This contributed to the annual value of 622.5% for FY2024, which is 5585100.0% down from last year.
  • ProPhase Labs' EBT Margin amounted to 792.3% in Q3 2025, which was down 2645400.0% from 296.15% recorded in Q2 2025.
  • ProPhase Labs' EBT Margin's 5-year high stood at 191.38% during Q4 2023, with a 5-year trough of 1247.83% in Q4 2024.
  • Its 5-year average for EBT Margin is 207.88%, with a median of 37.18% in 2023.
  • In the last 5 years, ProPhase Labs' EBT Margin plummeted by -14392200bps in 2024 and then soared by 2191400bps in 2025.
  • Over the past 5 years, ProPhase Labs' EBT Margin (Quarter) stood at 21.31% in 2021, then tumbled by -212bps to 23.78% in 2022, then skyrocketed by 905bps to 191.38% in 2023, then crashed by -752bps to 1247.83% in 2024, then surged by 37bps to 792.3% in 2025.
  • Its EBT Margin was 792.3% in Q3 2025, compared to 296.15% in Q2 2025 and 326.9% in Q1 2025.